TrialFuture oncology (London, England)2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Pankit Vachhani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.